Epix Medical and InSightec of Israel have allied to investigate the use of Epix's vascular MRI contrast agent, MS-325, to facilitate the treatment of tumors under MRI guidance. InSightec develops devices and software for MRI-guided high-intensity focused
Epix Medical and InSightec of Israel have allied to investigate the use of Epix's vascular MRI contrast agent, MS-325, to facilitate the treatment of tumors under MRI guidance. InSightec develops devices and software for MRI-guided high-intensity focused ultrasound, an investigational method of heating and destroying tumors or tissue such as uterine fibroids with millimeter precision. The collaboration will initially focus on preclinical studies leading to future use in the image-guided therapy program at Brigham and Women's Hospital in Boston. Epix and InSightec will share information on their technologies to optimize the use of contrast agents during interventional procedures.
© 2001 Miller Freeman Inc.
3/28/01, Issue # 1506, page 4.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.